Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Inclusion Criteria: * Aged 18 years to 70 years, female * Patients with histologically-confirmed breast cancer and plan to accept adjuvant chemotherapy(epirubicin plus cyclophosphamide) * Have an Eastern Cooperative Oncology Group(ECOG) performance status≤2 * Have no clinically significant impairment in cardiac, liver and kidney * Adequate hematologic, hepatic and renal function which should meet the following requirements: 1. Absolute neutrophil count(ANC)≥1.5 x 10\^9/L 2. Blood platelet(PLT)≥100 x 10\^9/L 3. Serum creatinine(sCr)≤1.5 times the upper limit of normal(ULN) 4. Total bilirubin(TBIL)≤1.5×ULN 5. Aspartate aminotransferase(AST) /serum glutamic-oxaloacetic transaminase(SGOT) and/or alanine aminotransferase(ALT)/serum glutamic pyruvic transaminase(SGPT) ≤ 2.5 x ULN 6. Hemoglobin(Hb)\>9 g/dL 7. Alkaline phosphatase(ALP)≤1.5×ULN * Expected to comply with protocol * With urine human chorionic gonadotropin (hCG) negative * Signed informed consent Exclusion Criteria: * With acute infection * With history of bone marrow transplant and/or stem cell transplant * With primary hematological diseases, such as myelodysplastic syndromes, aplastic anemia, sickle cell anemia * Received surgery within 3 weeks before chemotherapy * Received G-CSF within 4 weeks before involved in this study * Females who are pregnant or lactating * Participated in other clinical trials at the same time or within 4 weeks before screening * Known allergy to chemotherapy drugs,recombinant human granulocyte-colony stimulating factor rh(rhG-CSF) or any other biological products * With cacoethic addiction such as drug abuse or alcoholism * With other cases which is not suitable for this study judged by investigator